Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, proprietary programming software, radiofrequency ablation, indirect decompression systems, and intraosseous nerve ablation and deep brain stimulation systems. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat, and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Boston Scientific Corporation

Goldman Sachs analyst David Roman maintained a Buy rating on Boston Scientific yesterday and set a price target of $57.00. The company’s shares clo...

Goldman Sachs Keeps Their Buy Rating on Boston Scientific (BSX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Boston Scientific (BSX) and Ligand Pharma (LGND) wit...

Analysts Are Bullish on These Healthcare Stocks: Boston Scientific (BSX), Ligand Pharma (LGND)

Citi analyst Joanne Wuensch maintained a Buy rating on Boston Scientific on July 6 and set a price target of $70.00. The company’s shares closed ye...

Citi Reaffirms Their Buy Rating on Boston Scientific (BSX)

Healthcare remains one of the market’s most steady sectors this year, backed by biotech innovation and medical device strength. According to analys...

3 Healthcare Stocks with Strong Upside to Consider in July 2026, According to Analysts

Boston Scientific ($BSX) announced an update on their ongoing clinical study. Boston Scientific is launching a new post-approval study called “A Po...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BSX	$44.25	+1.54%	20.69M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BSX	$44.25	+1.5%	20.69M
3
4
5
6

BSX

BSX

Get Boston Scientific Corporation Data in Excel

Get Boston Scientific Corporation Data in Excel